The estimated Net Worth of Anthony Dias is at least $115 millier dollars as of 12 February 2013. Anthony Dias owns over 2,000 units of Delcath Systems stock worth over $114,540 and over the last 12 years Anthony sold DCTH stock worth over $0.
Anthony has made over 2 trades of the Delcath Systems stock since 2013, according to the Form 4 filled with the SEC. Most recently Anthony exercised 2,000 units of DCTH stock worth $15,100 on 12 February 2013.
The largest trade Anthony's ever made was exercising 3,000 units of Delcath Systems stock on 4 January 2013 worth over $22,650. On average, Anthony trades about 500 units every 4 days since 2013. As of 12 February 2013 Anthony still owns at least 11,500 units of Delcath Systems stock.
You can see the complete history of Anthony Dias stock trades at the bottom of the page.
Anthony's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK, NY, 10019.
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel et Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems executives and other stock owners filed with the SEC include: